News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
273,744 Results
Type
Article (14255)
Company Profile (105)
Press Release (259376)
Multimedia
Podcasts (65)
Webinars (13)
Section
Business (88273)
Career Advice (466)
Deals (15392)
Drug Delivery (73)
Drug Development (36717)
Employer Resources (50)
FDA (6381)
Job Trends (6232)
News (150710)
Policy (14136)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (442)
Accelerated approval (13)
Adcomms (8)
Allergies (67)
Alliances (23318)
ALS (56)
Alzheimer's disease (477)
Antibody-drug conjugate (ADC) (98)
Approvals (6569)
Artificial intelligence (200)
Autoimmune disease (39)
Automation (10)
Bankruptcy (150)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (117)
Biotechnology (40)
Bladder cancer (38)
Brain cancer (30)
Breast cancer (168)
Cancer (1310)
Cardiovascular disease (151)
Career advice (417)
Career pathing (13)
CAR-T (48)
CDC (6)
Cell therapy (149)
Cervical cancer (9)
Clinical research (32015)
Collaboration (719)
Compensation (321)
Complete response letters (33)
COVID-19 (778)
CRISPR (43)
C-suite (427)
Cystic fibrosis (58)
Data (1813)
Denatured (18)
Depression (45)
Diabetes (126)
Diagnostics (1381)
Digital health (8)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (113)
Drug pricing (112)
Drug shortages (12)
Duchenne muscular dystrophy (80)
Earnings (33447)
Editorial (19)
Employer branding (4)
Employer resources (45)
Events (38964)
Executive appointments (527)
FDA (7474)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (425)
Gene editing (69)
Generative AI (18)
Gene therapy (165)
GLP-1 (438)
Government (1405)
Grass and pollen (4)
Guidances (163)
Healthcare (3576)
HIV (11)
Huntington's disease (8)
IgA nephropathy (37)
Immunology and inflammation (68)
Immuno-oncology (14)
Indications (50)
Infectious disease (840)
Inflammatory bowel disease (73)
Inflation Reduction Act (7)
Influenza (23)
Intellectual property (112)
Interviews (60)
IPO (5914)
IRA (33)
Job creations (2055)
Job search strategy (374)
JPM (28)
Kidney cancer (9)
Labor market (28)
Layoffs (205)
Leadership (8)
Legal (3449)
Liver cancer (22)
Longevity (8)
Lung cancer (182)
Lymphoma (123)
Machine learning (13)
Management (17)
Manufacturing (408)
MASH (67)
Medical device (1302)
Medtech (1308)
Mergers & acquisitions (9895)
Metabolic disorders (432)
Multiple sclerosis (46)
NASH (14)
Neurodegenerative disease (82)
Neuropsychiatric disorders (36)
Neuroscience (884)
Neurotech (1)
NextGen: Class of 2026 (1588)
Non-profit (600)
Now hiring (18)
Obesity (225)
Opinion (141)
Ovarian cancer (39)
Pain (108)
Pancreatic cancer (51)
Parkinson's disease (80)
Partnered (11)
Patents (221)
Patient recruitment (116)
Peanut (12)
People (29738)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase 1 (8303)
Phase 2 (13516)
Phase 3 (12211)
Pipeline (1875)
Policy (134)
Postmarket research (1401)
Preclinical (3338)
Press Release (25)
Prostate cancer (84)
Psychedelics (15)
Radiopharmaceuticals (134)
Rare diseases (345)
Real estate (2659)
Recruiting (18)
Regulatory (10948)
Reports (15)
Research institute (573)
Resumes & cover letters (55)
Rett syndrome (5)
RNA editing (6)
RSV (19)
Schizophrenia (69)
Series A (80)
Series B (47)
Service/supplier (2)
Sickle cell disease (46)
Special edition (10)
Spinal muscular atrophy (80)
Sponsored (9)
Startups (1644)
State (2)
Stomach cancer (5)
Supply chain (48)
Tariffs (68)
The Weekly (45)
Vaccines (231)
Venture capital (32)
Weight loss (139)
Women's health (26)
Worklife (4)
Date
Today (34)
Last 7 days (191)
Last 30 days (830)
Last 365 days (10508)
2026 (858)
2025 (10712)
2024 (12499)
2023 (14250)
2022 (19558)
2021 (20070)
2020 (19034)
2019 (14893)
2018 (11717)
2017 (13888)
2016 (13129)
2015 (15474)
2014 (12423)
2013 (10593)
2012 (11401)
2011 (11923)
2010 (10888)
Location
Africa (318)
Alabama (18)
Alaska (1)
Arizona (77)
Arkansas (3)
Asia (20882)
Australia (2687)
California (3161)
Canada (1473)
China (547)
Colorado (142)
Connecticut (129)
Delaware (123)
Europe (40858)
Florida (598)
Georgia (63)
Hawaii (1)
Idaho (10)
Illinois (345)
India (43)
Indiana (238)
Iowa (2)
Japan (243)
Kansas (77)
Kentucky (20)
Louisiana (3)
Maine (2)
Maryland (419)
Massachusetts (2579)
Michigan (46)
Minnesota (165)
Mississippi (1)
Missouri (33)
Montana (8)
Nebraska (7)
Nevada (16)
New Hampshire (8)
New Jersey (1392)
New Mexico (7)
New York (902)
North Carolina (615)
North Dakota (2)
Northern California (1441)
Ohio (80)
Oklahoma (5)
Oregon (18)
Pennsylvania (712)
Puerto Rico (12)
Rhode Island (17)
South America (506)
South Carolina (10)
Southern California (1376)
Tennessee (53)
Texas (452)
United States (12611)
Utah (58)
Virginia (159)
Washington D.C. (42)
Washington State (221)
West Virginia (1)
Wisconsin (37)
Wyoming (1)
273,744 Results for "braeburn pharmaceutical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Braeburn Announces Publication of a Post Hoc Analysis of Data from Patients Using Fentanyl Treated with BRIXADI in a Phase 3 Efficacy and Safety Study
Braeburn Inc. announces the publication of a post hoc analysis in the Journal of the American Medical Association (JAMA) Network Open.
June 25, 2024
·
12 min read
FDA
Braeburn’s Long-Acting Brixadi Receives FDA Clearance to Treat Opioid Use Disorder
The FDA approved Braeburn Pharmaceuticals’ new buprenorphine treatment option with extended-release medication that could pave the way for greater patient compliance.
May 25, 2023
·
3 min read
·
Lisa Munger
Press Releases
Insilico Medicine Launches Science MMAI Gym to Transform Frontier LLMs into Pharmaceutical-Grade Scientific Engines
January 22, 2026
·
1 min read
Pharm Country
Braeburn’s BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection (CIII) Receives FDA Approval for Moderate to Severe Opioid Use Disorder
Braeburn announces that the U.S. Food and Drug Administration (FDA) has approved BRIXADI (buprenorphine) extended-release injection for subcutaneous use (CIII), a new weekly and monthly medication for moderate to severe opioid use disorder (OUD).
May 23, 2023
·
12 min read
Press Releases
Kiniksa Pharmaceuticals Provides Corporate Update
January 12, 2026
·
11 min read
Press Releases
Kye Pharmaceuticals Announces Licensing and Distribution Agreement with Neurim Pharmaceuticals for SLENYTO® in Canada
January 13, 2026
·
5 min read
Sponsored
Best Pharmaceutical Label Manufacturers: Reviews and Comparisons
Selecting the ideal pharmaceutical label manufacturer requires careful consideration. This article compares leading companies, highlighting their strengths in regulatory compliance, material performance, serialization, innovation, and sustainability, to help you make an informed decision for your product’s safety and success.
October 27, 2025
·
6 min read
Press Releases
USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
February 2, 2026
·
4 min read
Press Releases
Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics
February 4, 2026
·
1 min read
Press Releases
Pharmaceutical Service Provider Vetter Pharma to Build New Manufacturing Site in Germany
Strategic Investments in the EU and US strengthen Vetter’s Global Footprint • Building permit application for German site submitted • Construction start is scheduled for the 2nd quarter 2026, with operational readiness in 2031 • Expansions in the US and Europe are included in a €1.5 billion investment plan
January 29, 2026
·
1 min read
1 of 27,375
Next
